Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

USA - NASDAQ:SUPN - US8684591089 - Common Stock

46.98 USD
+0.94 (+2.04%)
Last: 9/22/2025, 4:30:01 PM
46.98 USD
0 (0%)
After Hours: 9/22/2025, 4:30:01 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to SUPN. SUPN was compared to 196 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues. SUPN has a correct valuation and a medium growth rate. These ratings could make SUPN a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year SUPN was profitable.
In the past year SUPN had a positive cash flow from operations.
In the past 5 years SUPN has always been profitable.
SUPN had a positive operating cash flow in each of the past 5 years.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

SUPN has a Return On Assets of 4.67%. This is amongst the best in the industry. SUPN outperforms 87.24% of its industry peers.
With an excellent Return On Equity value of 6.06%, SUPN belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
SUPN has a Return On Invested Capital of 4.10%. This is amongst the best in the industry. SUPN outperforms 81.63% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 15.28%.
The 3 year average ROIC (2.70%) for SUPN is below the current ROIC(4.10%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROIC 4.1%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

SUPN has a Profit Margin of 9.70%. This is amongst the best in the industry. SUPN outperforms 85.20% of its industry peers.
In the last couple of years the Profit Margin of SUPN has declined.
With an excellent Operating Margin value of 10.98%, SUPN belongs to the best of the industry, outperforming 84.18% of the companies in the same industry.
SUPN's Operating Margin has declined in the last couple of years.
SUPN's Gross Margin of 89.87% is amongst the best of the industry. SUPN outperforms 94.39% of its industry peers.
SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SUPN has more shares outstanding
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 6.49 indicates that SUPN is not in any danger for bankruptcy at the moment.
SUPN's Altman-Z score of 6.49 is amongst the best of the industry. SUPN outperforms 80.61% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.49
ROIC/WACC0.42
WACC9.8%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

SUPN has a Current Ratio of 2.58. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.58, SUPN is in line with its industry, outperforming 47.45% of the companies in the same industry.
SUPN has a Quick Ratio of 2.43. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.43, SUPN perfoms like the industry average, outperforming 51.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.43
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.93% over the past year.
Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.93% on average per year.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.54%.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%

3.2 Future

Based on estimates for the next years, SUPN will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.47% on average per year.
The Revenue is expected to grow by 10.74% on average over the next years. This is quite good.
EPS Next Y-23.13%
EPS Next 2Y-8.21%
EPS Next 3Y9.72%
EPS Next 5Y18.47%
Revenue Next Year7.27%
Revenue Next 2Y12.58%
Revenue Next 3Y13%
Revenue Next 5Y10.74%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 14.41, the valuation of SUPN can be described as correct.
Based on the Price/Earnings ratio, SUPN is valued cheaply inside the industry as 86.73% of the companies are valued more expensively.
SUPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.38.
The Price/Forward Earnings ratio is 18.90, which indicates a rather expensive current valuation of SUPN.
Based on the Price/Forward Earnings ratio, SUPN is valued a bit cheaper than the industry average as 77.04% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SUPN to the average of the S&P500 Index (22.86), we can say SUPN is valued inline with the index average.
Industry RankSector Rank
PE 14.41
Fwd PE 18.9
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

87.76% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 87.24% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.17
EV/EBITDA 10.94
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of SUPN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.08
EPS Next 2Y-8.21%
EPS Next 3Y9.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (9/22/2025, 4:30:01 PM)

After market: 46.98 0 (0%)

46.98

+0.94 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners109.54%
Inst Owner Change0.42%
Ins Owners4.2%
Ins Owner Change1.61%
Market Cap2.63B
Analysts80
Price Target44.68 (-4.9%)
Short Float %8.94%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.64%
Min EPS beat(2)15.55%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)84.8%
Min EPS beat(4)15.55%
Max EPS beat(4)158.74%
EPS beat(8)7
Avg EPS beat(8)81.53%
EPS beat(12)8
Avg EPS beat(12)38.3%
EPS beat(16)10
Avg EPS beat(16)29.24%
Revenue beat(2)1
Avg Revenue beat(2)2.29%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)6.02%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.08%
Revenue beat(12)8
Avg Revenue beat(12)2.78%
Revenue beat(16)11
Avg Revenue beat(16)2.43%
PT rev (1m)8.96%
PT rev (3m)12.89%
EPS NQ rev (1m)-27.43%
EPS NQ rev (3m)-46.42%
EPS NY rev (1m)4.87%
EPS NY rev (3m)7.15%
Revenue NQ rev (1m)2.16%
Revenue NQ rev (3m)11.4%
Revenue NY rev (1m)1.37%
Revenue NY rev (3m)10.17%
Valuation
Industry RankSector Rank
PE 14.41
Fwd PE 18.9
P/S 3.96
P/FCF 14.17
P/OCF 14.08
P/B 2.48
P/tB 5.66
EV/EBITDA 10.94
EPS(TTM)3.26
EY6.94%
EPS(NY)2.49
Fwd EY5.29%
FCF(TTM)3.31
FCFY7.06%
OCF(TTM)3.34
OCFY7.1%
SpS11.86
BVpS18.97
TBVpS8.3
PEG (NY)N/A
PEG (5Y)2.08
Profitability
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROCE 6.66%
ROIC 4.1%
ROICexc 7.83%
ROICexgc N/A
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
FCFM 27.94%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.48%
Cap/Sales 0.18%
Interest Coverage 250
Cash Conversion 121.69%
Profit Quality 288.18%
Current Ratio 2.58
Quick Ratio 2.43
Altman-Z 6.49
F-Score8
WACC9.8%
ROIC/WACC0.42
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
EPS Next Y-23.13%
EPS Next 2Y-8.21%
EPS Next 3Y9.72%
EPS Next 5Y18.47%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%
Revenue Next Year7.27%
Revenue Next 2Y12.58%
Revenue Next 3Y13%
Revenue Next 5Y10.74%
EBIT growth 1Y56.36%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y21.99%
FCF growth 1Y161.05%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y160.89%
OCF growth 3Y10.6%
OCF growth 5Y3.74%